Beacon NewsFlashes – May 20, 2011
Myeloma Experts From The John Theurer Cancer Center To Field Questions At The Beacon Forums Next Week – During the week of May 23 through 27, multiple myeloma patients and caregivers will have the...
View ArticleBeacon NewsFlashes – September 26, 2011
Weekly Polls About Multiple Myeloma Have Started In The Beacon Forums – The Myeloma Beacon has started conducting “Weekly Polls” in the Beacon forums. These polls and their related discussions address...
View ArticleBeacon NewsFlashes – February 6, 2012
Viracept Demonstrates Anti-Myeloma Activity – Results of a recent preclinical trial show that Viracept (nelfinavir), alone or in combination with other common myeloma drugs, prevents myeloma cell...
View ArticleBeacon NewsFlashes – February 20, 2012
OncoPep and Dana-Farber Sign License Agreement For Myeloma Vaccine Technology – The biotechnology company OncoPep has signed a license agreement with the Dana-Farber Cancer Institute in Boston to...
View ArticleBeacon NewsFlashes – August 15, 2012
Phase 1 Trial Of All-Oral Rocilinostat-Revlimid-Dexamethasone Combo Begins – Acetylon Pharmaceuticals announced last week the initiation of a Phase 1b clinical trial of rocilinostat (ACY-1215) in...
View ArticleASH 2012 Multiple Myeloma Update – Day Three: Poster Sessions
Monday was the third and next-to-last day of the 2012 American Society of Hematology (ASH) annual meeting. It also was the busiest day of the meeting in regard to myeloma-related research. The day...
View ArticleThe Future Of Treatment For Multiple Myeloma
In a recent review article published in the journal Clinical Cancer Research, two myeloma experts from the Dana-Farber Cancer Institute, Dr. Nikhil Munshi and Dr. Kenneth Anderson, review the latest...
View ArticleASH 2013 Preview: Treatments In Early-Phase Clinical Development For Multiple...
This article is the second in The Beacon’s ‘preview’ series about myeloma research that will be presented at the American Society of Hematology (ASH) meeting in early December. Abstracts for...
View Article
